Strategic partnerships Leverage MabVax’s history of collaborations with prestigious labs and cancer centers (Memorial Sloan Kettering, Rockefeller University, Sarah Cannon, Honor Health, Imaging Endpoints) to propose co-development, sponsored research, or technology licensing opportunities that expand their clinical discovery platform.

Clinical stage leverage Target opportunities around their Phase 1 assets such as MVT-5873 and MVT-1075 for CRO services, imaging diagnostics, and radiopharmaceutical development partnerships with pharma companies seeking early-stage oncology candidates.

Strategic buyer potential Recognize BioNTech’s prior acquisition of MabVax assets as a signal of strategic value; position serial biotech buyers or larger pharma looking to expand in immuno-oncology, radiotherapy, or antibody platforms for potential asset acquisition or licensing discussions.

Funding signals With multiple rounds of funding and a stated revenue range, identify opportunities for milestone-based collaborations, co-invested clinical programs, or grant-supported research that align with MabVax’s development timeline and risk profile.

Operational footprint Note the relocation and asset transfer history to San Diego and the small employee base; offer lightweight, scalable external CRO/CMO partnerships and flexible collaboration models that minimize internal headcount while accelerating clinical milestones.